A world-class management team experienced in gene therapy, rare disease drug development and commercialization, and biologics manufacturing.
Andrew Krivoshik, M.D., Ph.D.
President and Head of Development
Andrew Krivoshik, M.D., Ph.D. is President and Head of Development, Northbrook, IL, providing strategic direction and leadership across all global therapeutic area development programs.
Andy has most recently served as Senior Vice President and Head of Development Therapeutic Areas. He has experience in global clinical development, biomarker strategy, translational medicine, product and patient safety, and medical affairs. Prior to joining Astellas, he was a Senior Medical Director at Abbott and was a graduate of the Abbott Physician Development Program.
As a pharmaceutical physician, he has led and managed global multidisciplinary cross-functional teams, successfully implemented novel and innovative clinical trial designs, and functioned as a subject matter expert and primary author of clinical protocols, investigator brochures and regulatory submissions spanning the life cycle of clinical development including Investigational New Drug and New Drug Application/Marketing Authorization Application filings.
Dr. Krivoshik holds a BSE in Electrical Engineering with honors from Princeton University, an M.D. from the University of Illinois (UIC) College of Medicine at Urbana-Champaign, and a Ph.D. in biophysics and computational biology from the University of Illinois at Urbana-Champaign. He received his clinical internship and residency training in pediatric and adolescent medicine at Mayo Clinic, and clinical pediatric hematology and oncology fellowship training at Duke University. He is licensed in multiple jurisdictions as both a physician and professional engineer and has served as an invited speaker and session chair at international scientific congresses.
Morten Sogaard, Ph.D.
Senior Vice President, Gene Therapy Research & Technical Operations
Morten Sogaard, Ph.D. is Senior Vice President, Gene Therapy Research and Technical Operations for Astellas Gene Therapies. He is responsible for advancing the company’s pipeline from discovery through to IND-enabling preclinical development and for all Manufacturing, Technical Development, Supply chain and Facilities & Engineering.
Prior to joining Astellas Gene Therapies in May 2022, Morten was Head of Target Sciences at Pfizer and served as a member of the global R&D Leadership Team. Morten also held various leadership roles at Pfizer in Diagnostics, Genomics, Genetics and Computational Capabilities, as well as External R&D for Platform Technologies and Oncology.
Prior to Pfizer, Morten led Immuno-Oncology research at Pharmacia, headed the Global Enabling Technologies and Research Informatics at Boehringer Ingelheim, and oversaw Molecular Sciences research at AstraZeneca.
Morten has a Ph. D. in Biochemistry with focus on protein engineering from the University of Copenhagen and completed his postdoctoral studies with Nobel Laureate Jim Rothman at Rockefeller Research Labs, MSKCC, New York.
Division Head of Gene Therapy Commercial
Amy Pott is Division Head of Gene Therapy, Commercial for Astellas Gene Therapies, and is responsible for leading commercialization of our Gene Therapy business. She joined Astellas Gene Therapies (formerly Audentes Therapeutics) in January 2021 and brings an impressive amount of experience and expertise around rare disease therapies.
Ms. Pott joined Astellas Gene Therapies (formerly Audentes Therapeutics) from Swedish Orphan Biovitrum (SOBI), where she was President, North America, and oversaw rare disease and specialty programs. Prior to joining SOBI, Ms. Pott was Group Vice President, US Franchise Head, Internal Medicine & Oncology at Shire, where she was responsible for four rare disease businesses. She joined Shire when the company acquired Baxalta and stayed on to build the US commercial operations group handling the US franchises.
Ms. Pott earned her B.A. in History from the University of Bristol and her M.Sc. in European Policy & International Relations from the London School of Economics.
Senior Vice President, Primary Focus Lead – Genetic Regulation
Richard Wilson is currently the Senior Vice President, Primary Focus Lead of Genetic Regulation at Astellas Gene Therapies (formerly Audentes Therapeutics) and is responsible for setting and leading the gene therapy strategy for Astellas’ Primary Focus Genetic Regulation. Richard joined Audentes in April 2020 as Vice President, Program Management.
Richard has over 25 years of experience in research, development, and commercialization of small molecules, biological and gene therapies. Prior to Audentes, he served as Executive Director, Product Portfolio Development at BioMarin Pharmaceutical Inc. where he held a number of roles including portfolio Core Team leader for BioMarin’s PKU franchise, overseeing the approval and global launch of Palynziq, the first enzyme substitution therapy for PKU.
Prior to BioMarin, Richard held leadership positions in GlaxoWellcome, BioChem Pharma, Theravance and Innoviva, where he was involved in the development and commercialization of a range of products in COPD and Asthma – Relvar/Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta, and also in the identification of a nebulized delivery strategy for revefenacin (Yupelri). He has also led R&D programs in anti-infective, cardiovascular, rheumatology, and urology disease areas.
Richard holds a BSc (Hons) in Chemistry from the University of Manchester and an MBA from the Haas School of Business at UC Berkeley, where he serves on the Board of Directors for UC Berkeley Executive Education.
Our Center of Excellence Leadership Forum sets the Strategy for the Gene Therapy Center of Excellence and comprises key leaders from throughout the COE:
Andy Krivoshik, President and Head of Development
Amy Pott, Division Head of Gene Therapy Commercial
Morten Sogaard, Ph.D., Senior Vice President, Gene Therapy Research & Technical Operations
Richard Wilson, Senior Vice President, Primary Focus Lead – Genetic Regulation
Lovena D. Chaput, Senior Vice President, Americas
David Smethurst, Vice President and Head of Regulatory Affairs
Jason Schwartz, Vice President, Medical Affairs